Seres Therapeutics
MCRB
69 hedge funds and large institutions have $1.03B invested in Seres Therapeutics in 2015 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 13 reducing their positions, and 6 closing their positions.
162% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 13
151% more capital invested
Capital invested by funds: $409M → $1.03B (+$619M)
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
86% more call options, than puts
Call options by funds: $4M | Put options by funds: $2.15M
15% more funds holding
Funds holding: 60 → 69 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$15M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$12.4M |
| 3 |
BM
Bridger Management
New York
|
+$5.91M |
| 4 |
JP Morgan Chase
New York
|
+$4.42M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$7.31M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$4.99M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$3.61M |
| 4 |
O
OrbiMed
New York
|
-$2.63M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.78M |
MCRB Hedge Fund Activity: Q4 2015 in Review
69 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q4 2015, worth a combined $1.03B — up 151% from $409M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new MCRB positions and 6 closed out — a net gain of 9 holders — while 34 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $15M. The largest seller was RA Capital Management, exiting entirely with an estimated $7.31M sold.
- 69 institutional investors held Seres Therapeutics (MCRB) as of Q4 2015, up from 60 in Q3 2015.
- Funds reported $1.03B of Seres Therapeutics stock for Q4 2015, up 151% quarter-over-quarter.
- 15 funds opened new Seres Therapeutics positions in Q4 2015 and 6 closed out, a net change of +9 holders.
- The largest Seres Therapeutics buyer in Q4 2015 was BlackRock Fund Advisors, an estimated $15M added.
- The largest Seres Therapeutics seller in Q4 2015 was RA Capital Management, an estimated $7.31M sold.
Based on aggregated 13F filings for Q4 2015.